Xenova hails key treatments

British biotech firm Xenova today said it was making progress with its key cancer and anti-addiction drugs as it posted a 3% fall in half-yearly operating losses to £8.1m (€12.1m).

Slough-based Xenova said its most advanced product, the TransMID treatment for brain cancer, entered phase three patient trials in May in the United States.